Filtered By:
Condition: Bleeding
Education: Study

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 7778 results found since Jan 2013.

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)
CONCLUSIONS: We observed a risk reduction of 5% with prasugrel vs clopidogrel, indicating comparable efficacy. There were no major safety issues for prasugrel.PMID:35599000 | DOI:10.5551/jat.63473
Source: Journal of Atherosclerosis and Thrombosis - May 22, 2022 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Masato Nakamura Kazuo Umemura Hajime Matsuo Nobuyuki Koyama Junko Tsutsumi Kazumi Kimura Source Type: research

Relevance of admission hyperglycaemia and diabetes mellitus to efficacy and safety of mechanical thrombectomy in stroke patients
CONCLUSIONS: Diabetes mellitus has a neutral effect on the angiographic and clinical outcomes of mechanical thrombectomy in stroke patients. It does not increase the risk of intracranial haemorrhage after instrumental therapy. It is admission hyperglycaemia, rather than diabetes mellitus, that is a predictor of poor functional status in patients treated with thrombectomy. According to our results, the patient's neurological status, age, and the outcome of thrombectomy are relevant to the functional status in the acute ischaemic stroke period.PMID:36394219 | DOI:10.5603/PJNNS.a2022.0063
Source: Neurologia i Neurochirurgia Polska - November 17, 2022 Category: Neurology Authors: Anetta Lasek-Bal Amadeusz Żak Łukasz Binek Sebastian Student Aleksandra Cie ślik Wies ław Bal Wiktor Rybicki Jolanta Kulawik-Szwajca Source Type: research

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of randomized controlled trials
Conclusions: Aspirin plus dipyridamole combination therapy was beneficial in reducing the recurrence of stroke, and did not increase the bleeding event. Hence, aspirin plus dipyridamole combination therapy is effective and safe for the secondary prevention of stroke.
Source: Journal of the Neurological Sciences - July 19, 2013 Category: Neurology Authors: Xia Li, Guoyu Zhou, Xueying Zhou, Shengnian Zhou Tags: Original Articles Source Type: research

Association between periodontal disease and non-fatal ischemic stroke: a case-control study.
Conclusion. This case-control study demonstrates that periodontal disease, especially markers such as BOP and bone loss, is independently associated with ischemic stroke. PMID: 24720864 [PubMed - as supplied by publisher]
Source: Acta Odontologica Scandinavica - April 11, 2014 Category: Dentistry Authors: Lafon A, Tala S, Ahossi V, Perrin D, Giroud M, Béjot Y Tags: Acta Odontol Scand Source Type: research

Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study Brief Reports
Conclusions— Female patients with atrial fibrillation had higher ischemic stroke rates compared with male patients, but the relative effects of apixaban compared with aspirin on both ischemic stroke and bleeding were similar in men and women.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lip, G. Y. H., Eikelboom, J., Yusuf, S., Shestakovska, O., Hart, R. G., Connolly, S., on behalf of the AVERROES Investigators Tags: Other anticoagulants, Thrombosis risk factors Brief Reports Source Type: research

THrombolysis for Acute Wake‐up and unclear‐onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
DiscussionThis trial may help determine if low‐dose alteplase at 0·6 mg/kg should be recommended as a routine clinical strategy for ischemic stroke patients with unclear‐onset time.
Source: International Journal of Stroke - August 4, 2014 Category: Neurology Authors: Masatoshi Koga, Kazunori Toyoda, Kazumi Kimura, Haruko Yamamoto, Makoto Sasaki, Toshimitsu Hamasaki, Takanari Kitazono, Junya Aoki, Kenta Seki, Kazunari Homma, Shoichiro Sato, Kazuo Minematsu, Tags: Protocols Source Type: research

Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation.
Conclusion: Aspirin use increased amongst newly diagnosed Chinese AF patients with no relationship to the patient's stroke or bleeding risk. Warfarin use was very low. Given the healthcare burden of AF and its complications, our study has major implications for healthcare systems in non-Western countries, given the global burden of this common arrhythmia. PMID: 25501045 [PubMed - as supplied by publisher]
Source: Chest - December 11, 2014 Category: Respiratory Medicine Authors: Guo Y, Wang H, Tian Y, Wang Y, Lip GY Tags: Chest Source Type: research

Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA 2 DS 2 -VASc Score
ConclusionsLow-risk patients (CHA2DS2-VASc = 0 [male], 1 [female]) have a truly low risk for stroke and bleeding. With 1 additional stroke risk factor (CHA2DS2-VASc = 1 [male], = 2 [female]), there was a significant increase in event rates (particularly mortality) if nonanticoagulated.
Source: Journal of the American College of Cardiology - April 6, 2015 Category: Cardiology Source Type: research

Cortical Superficial Siderosis and Risk of Bleeding after Thrombolysis for Ischemic Stroke
Conclusions: The prevalence of CSS in a clinical cohort of stroke patients that received IVT was low and thus does not appear to pose a substantial risk for symptomatic ICH although this may occur in individual patients. However, such analysis also needs to be extended to the very old stroke patients in whom IVT is increasingly used.Cerebrovasc Dis 2015;40:191-197
Source: Cerebrovascular Diseases - September 9, 2015 Category: Neurology Source Type: research

Novel Diagnostic and Monitoring Tools in Stroke: an Individualized Patient-Centered Precision Medicine Approach.
Authors: de Villiers S, Swanepoel A, Bester J, Pretorius E Abstract Central to the pathogenesis of ischaemic stroke are the normally protective processes of platelet adhesion and activation. Experimental evidence has shown that the ligand-receptor interactions in ischaemic stroke represent a thrombo-inflammatory cascade, which presents research opportunities into new treatment. However, as anti-platelet drugs have the potential to cause severe side effects in ischaemic stroke patients (as well as other vascular disease patients), it is important to carefully monitor the risk of bleeding and risk of thrombus in pati...
Source: Journal of Atherosclerosis and Thrombosis - December 23, 2015 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research